Behavioral and neurochemical effects of alpha lipoic acid associated with omega-3 in tardive dyskinesia induced by chronic haloperidol in rats

Canadian Journal of Physiology and Pharmacology
Dayane Pessoa de AraújoFausto Pierdoná Guzen


Tardive dyskinesia (TD) is characterized by involuntary movements of the lower portion of the face being related to typical antipsychotic therapy. TD is associated with the oxidative imbalance in the basal ganglia. Lipoic acid (LA) and omega-3 (ω-3) are antioxidants acting as enzyme cofactors, regenerating antioxidant enzymes. This study aimed to investigate behavioral and neurochemical effects of supplementation with LA (100 mg/kg) and ω-3 (1 g/kg) in the treatment of TD induced by chronic use of haloperidol (HAL) (1 mg/kg) in rats. Wistar male rats were used, weighing between 180-200 g. The animals were treated chronically (31 days) with LA alone or associated with HAL or ω-3. Motor behavior was assessed by open-field test, the catalepsy test, and evaluation of orofacial dyskinesia. Oxidative stress was accessed by determination of lipid peroxidation and concentration of nitrite. LA and ω-3 alone or associated caused an improvement in motor performance by increasing locomotor activity in the open-field test and decreased the permanence time on the bar in the catalepsy test and decreased the orofacial dyskinesia. LA and ω-3 showed antioxidant effects, decreasing lipid peroxidation and nitrite levels. Thus, the use of LA associ...Continue Reading


Oct 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·W M GlazerD C Moore
Jan 1, 1990·Methods in Enzymology·H H Draper, M Hadley
May 1, 1973·Animal Behaviour·J Archer
Apr 3, 1981·Science·L C GreenP Goldman
Aug 1, 1995·Free Radical Biology & Medicine·L PackerH J Tritschler
Jan 25, 2003·Pharmacology, Biochemistry, and Behavior·Pattipati S NaiduShrinivas K Kulkarni
May 24, 2003·Behavioural Processes·Silvânia Maria Mendes VasconcelosGlauce S.B. Viana
Jul 29, 2008·Advanced Drug Delivery Reviews·Annette MaczurekGerald Münch
May 16, 2009·Journal of Neural Transmission·S R Thaakur, G Himabindhu
Oct 24, 2009·Journal of Psychiatric Research·Seetharamaiah ChittiprolBangalore N Gangadhar
Jul 6, 2010·Arquivos de neuro-psiquiatria·Itala Mônica de Sales SantosRivelilson Mendes de Freitas
Dec 4, 2010·The International Journal of Neuroscience·Dayane Pessoa de AraújoSilvânia Maria Mendes Vasconcelos
Sep 16, 2011·Behavioural Pharmacology·Danielle Silveira MacêdoAndré Férrer Carvalho
Apr 16, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Márcia Calheiros Chaves SilvaSilvânia Maria Mendes Vasconcelos
Sep 12, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Dayane Pessoa de AraújoSilvânia Maria Mendes Vasconcelos


Jun 20, 2019·Current Protocols in Neuroscience·Fausto Pierdoná GuzenDayane Pessoa de Araújo
Dec 31, 2019·Oxidative Medicine and Cellular Longevity·Sávio Monteiro Dos SantosMarta Chagas Monteiro

Related Concepts

Tardive Dyskinesia
Behavior, Animal
Drug Interactions
Science of Neurochemistry
Lipid Peroxidation
Omega-3 Fatty Acids
Rats, Wistar

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here